Inhibitors of Animal Viruses by Compounds that Target TSG101-Ubiquitin Interaction

Host-directed viral inhibitors that target a highly conserved cellular machinery necessary for the viral life cycle. Background: HIV is a major global public health problem that lacks a cure, however available anti retrovirals have been successful in improving and extending the quality of life in patients. This success has recently encountered a set-back due to emergence of drug resistant variants of HIV. Therefore, increasing incidence and emerging resistance has resulted in a need to develop novel therapeutic intervention against these enveloped viruses. Technology Overview: Researchers at Stony Brook University have identified host-directed viral inhibitors that target a highly conserved cellular machinery necessary for the viral life cycle. The inhibitors target transport of viral particles, from cytoplasm to cell membrane, thus arresting viral dissemination process and resulting in clearance of infected cells by host immune system. The researchers have further demonstrated that the inhibitors are specific towards viruses and do not alter normal cellular function. Advantages: Broad spectrum anti-viral

Can be used as combination drug to further extend spectrum

Targets host factors, thus, less likely to induce resistance

One lead compound is FDA approved for another indication

Known to be safe in humans Applications: Infectious diseases

Therapeutics

Antiviral Intellectual Property Summary: Patent application submitted Stage of Development: A PCT application (PCT/US2017/059111) covering composition and methods of use is on file. Licensing Potential: Development partner,Commercial partner,Licensing Licensing Status: Available for License. Stony Brook University is seeking interested partners to develop and commercialize the technology. #8875 Additional Information: antiviral,antiviral compound,public health,resistance,novel therapeutic,therapeutic,therapeutic intervention,viral,inhibitor,cellular,cell membrane,immune system,anti-viral,lead compound,infectious disease,antiviral target,antivirals,viral control,viral disease,hiv,hiv drug,hiv research,hiv treatment,hiv inhibitor,antiretroviral,antiretroviral therapy,drug resistance,virus,host-virus,host-virus interaction https://stonybrook.technologypublisher.com/files/sites/xm7m109hrds2145cexwq_hiv.png Please note, header image is purely illustrative. Source: typographyimages, pixabay, CC0.

Patent Information:
Technology/Start-up ID: